0.12 (7.45%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Weak
Earnings
Very Strong
Earnings
Neutral
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
enGene Therapeutics Inc.
Telephone
1.514.332.4888
Address
Suite 220, 4868 Rue Levy, Saint-Laurent, QC H4R 2P1
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.4 - 12.25
Trade Value (12mth)
US$1,150,987.00
1 week
-6.4%
1 month
-81.15%
YTD
-81.81%
1 year
-62.47%
All time high
47.17
EPS 3 yr Growth
-120873.70%
EBITDA Margin
0.00%
Operating Cashflow
-$99m
Free Cash Flow Return
-40.80%
ROIC
-48.30%
Interest Coverage
-41.00
Quick Ratio
6.30
Shares Outstanding (Fully Diluted)
67m
HALO Sector
Other Finance
Next Company Report Date
23-Dec-26
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 09 March 26 | |
| 09 March 26 | |
| 09 March 26 | |
| 09 March 26 | |
| 09 March 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -151.22 | -1.46 | -2.29 | | | | ||
EPS (Fully Diluted) | $ | | | | | -151.22 | -1.46 | -2.29 | | | | ||
Growth | % | | | | | -7,959,247.4 | 99 | -57.2 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
